Aducanumab

GPTKB entity

Statements (57)
Predicate Object
gptkbp:instance_of gptkb:monoclonal_antibody
gptkbp:brand gptkb:Aduhelm
gptkbp:chemical_formula C6480 H10000 N1710 O2000 S44
gptkbp:class gptkb:immunotherapy
gptkbp:clinical_trial gptkb:Europe
gptkb:Canada
gptkb:United_States
Phase 3
gptkbp:clinical_trial_end_year gptkb:2019
gptkbp:clinical_trial_start_year gptkb:2015
gptkbp:collaborations collaboration with universities
collaboration with research institutes
gptkbp:competitors gptkb:Donanemab
gptkb:Lecanemab
gptkbp:controversy high cost
efficacy debate
gptkbp:developed_by gptkb:Biogen
gptkbp:discovery_year gptkb:2012
gptkbp:dosage_form solution for infusion
gptkbp:duration monthly
gptkbp:effective_date gptkb:2021
FDA approved
gptkbp:funding public and private funding
https://www.w3.org/2000/01/rdf-schema#label Aducanumab
gptkbp:indication mild cognitive impairment
mild Alzheimer's disease
gptkbp:invention patented
gptkbp:is_monitored_by recommended during treatment
gptkbp:knockouts high affinity for amyloid beta
gptkbp:launch_date gptkb:2021
gptkbp:marketed_as Biogen and Eisai
gptkbp:mechanism_of_action reduces amyloid plaques
gptkbp:patient_eligibility_criteria age criteria
biomarker confirmation
specific cognitive impairment
gptkbp:patient_population Alzheimer's patients
gptkbp:phase3_trial_name EMERGE
ENGAGE
gptkbp:provides_guidance_on included in Alzheimer's treatment guidelines
gptkbp:publication published in peer-reviewed journals
gptkbp:regulatory_body_approval gptkb:FDA
gptkb:EMA
gptkbp:research_focus gptkb:neurodegenerative_diseases
gptkbp:route_of_administration intravenous
gptkbp:service_frequency every 4 weeks
gptkbp:side_effect dizziness
headache
nausea
confusion
brain swelling
required by FDA
gptkbp:storage refrigerated
gptkbp:targets amyloid beta
gptkbp:used_for gptkb:neurodegenerative_diseases
gptkbp:weight 146 k Da
gptkbp:bfsParent gptkb:Biogen
gptkbp:bfsLayer 4